- |||||||||| furosemide / Generic mfg.
Journal: Prevalence of polypharmacy in Denmark. (Pubmed Central) - May 6, 2021 The prevalence of polypharmacy increased with age, and more than half of the population aged ≥ 75 years redeemed prescriptions for > 5 different medicines. The most redeemed medicines among older citizens were against pain and cardiovascular disease.
- |||||||||| furosemide / Generic mfg.
Journal: Pathophysiology of Diuretic Resistance and Its Implications for the Management of Chronic Heart Failure. (Pubmed Central) - May 1, 2021 Diuretic resistance implies a failure to increase fluid and sodium (Na) output sufficiently to relieve volume overload, edema, or congestion, despite escalating doses of a loop diuretic to a ceiling level (80 mg of furosemide once or twice daily or greater in those with reduced glomerular filtration rate or heart failure)...Nephron mechanisms include tubular tolerance that can develop even during the time that the renal tubules are exposed to a single dose of diuretic, or enhanced reabsorption in the proximal tubule that limits delivery to the loop, or an adaptive increase in reabsorption in the downstream distal tubule and collecting ducts that offsets ongoing blockade of Na reabsorption in the loop of Henle. These provide rationales for novel strategies including the concurrent use of diuretics that block these nephron segments and even sequential nephron blockade with multiple diuretics and aquaretics combined in severely diuretic-resistant patients with heart failure.
- |||||||||| furosemide / Generic mfg.
Trial completion date, Trial primary completion date: The Effect of Loop Diuretics on Severity and Outcome of Acute Kidney Injury (clinicaltrials.gov) - Apr 28, 2021 P=N/A, N=200, Active, not recruiting, Our findings show that synthetic fingerprints and subsequent deep learning analysis can be of use to identify patients with clinical characteristics associated with high-response rate and long-term survival. Trial completion date: Dec 2021 --> Oct 2022 | Trial primary completion date: Dec 2020 --> Oct 2022
- |||||||||| Trial completion, Enrollment change: ACEI or ARB and COVID-19 Severity and Mortality in US Veterans (clinicaltrials.gov) - Apr 28, 2021
P=N/A, N=22213, Completed, Trial completion date: Dec 2021 --> Oct 2022 | Trial primary completion date: Dec 2020 --> Oct 2022 Active, not recruiting --> Completed | N=10000 --> 22213
- |||||||||| vardenafil / Generic mfg., furosemide / Generic mfg.
Review, Journal, Adverse events: Otorhinolaryngological adverse effects of urological drugs. (Pubmed Central) - Apr 24, 2021 Dizziness was most common, but dry mouth, rhinitis, nasal congestion, epistaxis, hearing loss, tinnitus, and rhinorrhea were also reported. Therefore, doctors must be aware of these adverse effects to improve adherence to the treatment and to minimize damage to the health of patients.
- |||||||||| hydrochlorothiazide / Generic mfg., furosemide / Generic mfg.
Trial completion date, Trial primary completion date: ProDUCT-HF: Protocol of Diuretics Use in Congestive Therapy in Heart Failure (clinicaltrials.gov) - Apr 23, 2021 P4, N=300, Recruiting, Anastomotic stricture after Anderson and Hynes DP can be prevented by appropriate patient selection. Trial completion date: Apr 2021 --> Dec 2021 | Trial primary completion date: Mar 2021 --> Dec 2021
- |||||||||| furosemide / Generic mfg.
Trial completion date, Trial primary completion date: Treatment of Post-Operative Sinonasal Polyposis With Topical Furosemide (clinicaltrials.gov) - Apr 23, 2021 P2, N=100, Recruiting, Trial completion date: Apr 2021 --> Dec 2021 | Trial primary completion date: Mar 2021 --> Dec 2021 Trial completion date: Jun 2021 --> Jun 2024 | Trial primary completion date: Nov 2020 --> Nov 2023
|